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Life is highly complex and, as quantum physics would predict, follows the rule of 
“everything is possible with varying probabilities”. Accordingly, science may be 
sometimes as confusing as political debates, where the same matter is addressed in 
different and misleading ways even in the absence of a real controversy. The Viewpoint 
by Ahmed et al. provides a paradigmatic example of a debate about two theories for 
pemphigus pathogenesis, i.e. “Monopathogenic vs. multipathogenic explanations of 
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pemphigus pathophysiology”, both being possible but occurring with variable probabilities 
(1).  
The readers should consider as take home message the following points: 
1. Heterogeneity in pemphigus. Two major types of pemphigus have been described, 
pemphigus vulgaris (PV) and pemphigus foliaceus (PF). The vast majority of patients with 
PV and PF have mucous and/or cutaneous lesions (2) associated with IgG auto-
antibodies (Abs) against desmoglein (Dsg) 3 and/or Dsg1. The profile of anti-Dsg1 and 
anti-Dsg3 autoAbs mostly correlates with the clinical phenotype, determining occurrence 
of cutaneous and/or mucous membrane lesions. However, in up to 5-10% of cases, 
particularly in PV patients, this is not the case, thus indicating variations to a common 
theme.  Furthermore, in over the last decade the pemphigus group of diseases is has 
turned out to be more heterogeneous than originally thought, encompassing different 
entities with overlapping and immunopathological features.  
 
2. The clinical phenotype is determined by multiple factors. As observed in many 
immune-mediated and other diseases, the clinical phenotype in a given patient is affected 
by a variety of modifying factors, including gene polymorphisms, epigenetic makeup, 
defects in structural proteins, immune response molecules, signaling molecules, as well 
as environmental and exogenous factors, such as drugs. Their impact on the phenotype 
should  always be kept in mind in such a complex biological system as the human body. 
In addition, autoAb titers, their predominant IgG subclasses and recognized epitopes and 
antigens also influence disease expression. These observations support that additional 
physiological factors (e.g. shown in case of EGFR deletion (3)) do modulate the clinical 
phenotype (4). 
3. Pemphigus can be caused by anti-Dsg without non-Dsg autoAbs (the 
monopathogenic theory). Evidence that anti-Dsg1 and/or anti-Dsg3 autoAbs alone are 
sufficient for cell-cell dissociation in vitro and in vivo is indisputable and compelling. 
Among others, the phenotype of PV patients with Dsg3 without Dsg1 autoAbs is 
recapitulated by the monospecific anti-Dsg3 Ab AK23 alone (s1); after passive transfer 
into neonatal or adult mice, it consistently induces hair follicle and/or palate blisters, and 
when combined with anti-Dsg1 autoAbs, it provokes PV-like skin lesions (3, 5, 6, s2, s3). 
Similar results were reported with distinct cloned human Dsg3 autoAbs (7) (Table 1). In 
this context, the seemingly alternate phenotypes of Dsg mutations or deletion in human or 
mice, argued by authors of the multipathogenic theory, are not a strong argument. 
Mutations in a given gene induce a variety of phenotypes depending - among others - on 
the site of mutation and genetic background Furthermore, in our hands, Dsg3 knockout 
mice exhibit hair follicle and palate blisters like described above for PV/AK23 
(unpublished). This said, the reader should not be mistaken! The authors of the 
monopathogenic hypothesis, a virtual theory animating this debate, support that autoAbs 
to Dsg3/Dsg1 alone are sufficient. However, they do not claim exclusivity of the antigenic 
target.  
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There is one query against the “Dsg3/Dsg1 autoAb alone are sufficient” which seems 
compelling and stands on top of the list: “Epidermal integrity “does not ”primarily depend 
on the desmosomal expression of Dsg1 and Dsg3”. This query only point to is only “half 
of the story”. The idea that loss of transadhesion between Dsg molecules in desmosomes 
would be sufficient for blister induction has long evolved. Demonstrated multiple times 
(e.g. 3, 5, 6, s2, s3), the initial event of loss of transadhesion between Dsg3 molecules, 
certainly pathogenic, is not enough. Only when coupled with altered signal transduction 
mediated by Dsg3 cadherin receptors, to which autoAbs preferentially bind, will 
desmosomes start to lose their cohesive grip.  
Cadherins receptors are now widely acknowledged to survey a variety of signaling 
networks, including a mitochondrial cross talk, to dictate cell fate (7). Hence, in particular 
PV is not about loss of adhesion or adhesion of Dsg1 and Dsg3 in desmosomes in the 
first place but about altered signal transduction upon anti-Dsg3 autoAb binding to Dsg3 
receptors. It is without any question that these signal alterations can be mimicked by a 
variety of other factors which alone or together with Dsg autoAbs recapitulate or enhance 
the disease.    
4. Pemphigus can be caused/enhanced by requires both autoAbs to Dsgs and non-
Dsgs antigens (the multipathogenic theory). Autoimmune diseases are often 
characterized by a vast number of autoantigens which are not associated with 
pathogenicity. Different approaches, including cloning of pemphigus autoAbs from 
affected patients (unpublished), have allowed to characterize - besides pathogenic and 
non-pathogenic anti-Dsg autoAbs (7) additional Abs of different specificities and Ig 
isotype (such as IgAHowever), most of these autoAbs, including those targeting 
keratinocyte mitochondria (9), do not possess acantholytic potential on their own but may 
act synergistically with anti-Dsg3 antibodies to increase acantholysis. It has also been 
claimed that antibodies targeting keratinocyte mitochondria contribute to the process of 
acantholysis (Table1). One interesting exception are autoAbs to other desmosomal 
cadherins such as the desmocollins which can cause a pemphigus-like disease in 
humans without anti-Dsg autoAbs (8, s4). The observation that there are patients with a 
clinical pemphigus phenotype but lacking anti-Dsg autoAbs as well as Abs of other known 
specificity, such as anti-desmocollins, raises the question about the pertinence of a 
debate on about a monopathogenic or multipathogenic theory.  
5. Is it worth the debate? The statement that the “individual authors may or may not 
support one view or the other” found in the footnote of the Viewpoint of Ahmed et al well 
summarizes how the matter is challenging. The wealth of available data discussed in this 
viewpoint indeed convinces us of the extraordinary biological complexity of the 
pathogenesis of pemphigus making a scientific debate futile. For educational purposes, it 
is sometimes necessary to talk about major concepts (pemphigus pathogenesis is 
induced by autoAb against Dsgs) rather than exciting exceptions (other antigens and 
additional factors), paying the price in terms of loss of complexity. 
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Table 1. Survey of Dsg and non-Dsg autoAbs with pathogenic activity in pemphigus 
Antigens Pathogenic antibodies (mAb) References 
Dsg3 2 murine mAbs (AK23, AK19) s1 
Dsg3 8 murine mAbs (NAK1,2,4,7,8,9,10,11) s7 
Dsg3 2 human mAbs ((D3)3c/9; (D31)2/28) 
 
s8 
Dsg3 1 human mAb (PVMAB786) s9 
Dsg3 4 human mAbs (PVE 4-8, PV2 4.2, 
PV2 3.2, PV2-VH1-69) 
s10 
Dsg3 1 human mAb (F779) s11 
Dsg3 3 human mAbs (PVA224, PVB28, 
PVB124) 
s12 
Dsg1 2 human mAbs ((D31)2/29, (D1)11/10) 
 
s8 
Dsg1 2 human mAbs (3-07/1e 3-30/3h)  s13 
Dsg1 1 human mAb (F24-9) 
 
s14 
Desmocollin 3 
 
Polyclonal AutoAbs and 1 murine mAb 
(U114, Progen)   
8, s4 
Pemphaxin 
 
Polyclonal AutoAbs amplify the activity 
of anti-Dsg AutoAbs 
s5 
α9-acetylcholine 
receptor 
Polyclonal AutoAbs amplify the activity 
of anti-Dsg AutoAbs 
s6 
Anti-mitochondrial 
antibodies 
Polyclonal AutoAbs amplify the activity 
of anti-Dsg AutoAbs 
s15 
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